The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) by Ford Brendan A since 2006.
The trader's CIK number is 1236444.
At the time of the last reporting, Ford Brendan A was the EVP-Corporate Develo of Navidea Biopharmaceuticals, Inc.. (stock ticker symbol NAVB).
Also see all insider trading activities at Navidea Biopharmaceuticals, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2014 | NAVB | 10,000 | $10,300 | 0 | $0 | 0 | $0 |
2013 | NAVB | 25,000 | $42,550 | 0 | $0 | 0 | $0 |
2012 | NAVB | 5,000 | $13,200 | 0 | $0 | 0 | $0 |
2011 | NAVB | 20,000 | $50,199 | 0 | $0 | 0 | $0 |
2010 | NAVB | 30,000 | $52,470 | 0 | $0 | 0 | $0 |
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2006 | CAH | 0 | $0 | 10,350 | $699,699 | 23,850 | $519,487 |
1. Navidea Biopharmaceuticals, Inc. (NAVB)
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2014-11-10 | NAVB | Buy | 10,000 | 1.03 | 10,300 |
2013-11-08 | NAVB | Buy | 20,000 | 1.45 | 29,000 |
2013-03-15 | NAVB | Buy | 5,000 | 2.71 | 13,550 |
2012-09-12 | NAVB | Buy | 5,000 | 2.64 | 13,200 |
2011-08-19 | NEOP | Buy | 20,000 | 2.51 | 50,199 |
2010-11-15 | NEOP | Buy | 30,000 | 1.75 | 52,470 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2006-08-18 | CAH | Option Ex | 10,350 | 27.05 | 279,998 |
2006-08-18 | CAH | Sale | 8,850 | 67.60 | 598,277 |
2006-08-21 | CAH | Sale | 1,500 | 67.61 | 101,422 |
2006-01-31 | CAH | Option Ex | 13,500 | 17.74 | 239,489 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Ford Brendan A (EVP-Corporate Develo of Navidea Biopharmaceuticals, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.